Suchergebnisse
Suchergebnisse:
Acquisition International Magazine’s M&A Award 2022 for Best Cell & Gene Therapy Acquisition 2022. Juniper Biologics Pte Ltd, a top science-led pharmaceutical company focused on researching, developing and commercializing novel therapies.
3. Juli 2018 · Catalent, a global leader in drug delivery and development solutions, has agreed to buy Juniper Pharmaceuticals, a company with expertise in formulation development and bioavailability enhancement. The acquisition will expand Catalent's offerings and capabilities in early-phase product development and clinical-scale oral dose manufacturing.
Pipeline - Juniper Biologics. Pipeline for continuous benefit to patients. We’re working to identify more unmet medical needs and focus our research where it is needed most.
Juniper Biologics is a Singapore-based company that develops and commercialises novel therapies for oncology, rare/orphan diseases and gene therapy. It has operations in Asia, Australia, New Zealand, Middle East and Africa.
Chief Executive Officer. Raman Singh is Chief Executive Officer (CEO) of Juniper Biologics overseeing its global pharmaceutical operations. Prior to Juniper, Raman was CEO for Mundipharma and its operations in Latin America, the Middle East Africa and the Asia Pacific as well as the company’s Global Consumer Healthcare business.
Juniper Biologics Named “Pharmaceutical Company of the Year” at Corporate LiveWire Global Awards USA – English. Advancing Healthcare Innovation: Juniper Biologics Recognized as the Best Novel Therapy R&D and Commercialization Company 2024 by APAC Insider.
22. Apr. 2021 · Singapore: 15 April 2021 – Juniper Biologics, a science-led healthcare company focused on researching, developing & commercialising novel therapies, has announced the appointment of celebrated pharmaceutical executive Raman Singh to the role of Chief Executive.
